BioSpace News Archive

Ocugen, Inc. announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.

PTC Therapeutics, Inc. shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington’s disease patients.

NanoViricides, Inc. reports that the ultra-broad-spectrum antiviral NV-387, a clinical Phase II stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures.

Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development and execution of clinical trials, announces that Manish Agrawal MD, Co-founder and CEO, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.

Spur Therapeutics, formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference being held on June 27th, 2024.

Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced preclinical data from two separate research collaborations.

Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, presented progress across two of its preclinical programs, including first-time demonstration in NHPs of efficient in vivo rewriting at the SERPINA1 locus responsible for AATD.

NewGenIvf Group, a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, announced that the Company is continuing to actively evaluate the terms of the proposed reverse merger with COVIRIX Medical Pty Ltd.